one has to invest in people to generate revenue. While there will be some cashflow pressure on the short term due to additional salary, it is good that the announcement spell out the expectation from the newly hired senior employee - sales increase of at least 20% and return to profit for the division/subsidiary. One has to look as well the quality and experience of the new employee. I don't think Chris Dax will join CDX group if he didn't believe he can achieve those targets plus more.
- Forums
- ASX - By Stock
- CDX
- Ann: New Senior Appointments to Drive Revenue & Product Strategy
Ann: New Senior Appointments to Drive Revenue & Product Strategy, page-5
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CDX (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.65M |
Open | High | Low | Value | Volume |
6.2¢ | 6.3¢ | 6.0¢ | $29.05K | 470.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 57401 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.1¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 57401 | 0.059 |
1 | 17241 | 0.058 |
1 | 100000 | 0.057 |
1 | 125000 | 0.054 |
2 | 140000 | 0.053 |
Price($) | Vol. | No. |
---|---|---|
0.061 | 50000 | 1 |
0.062 | 83300 | 1 |
0.063 | 130000 | 1 |
0.064 | 130000 | 1 |
0.067 | 27625 | 2 |
Last trade - 15.05pm 09/08/2024 (20 minute delay) ? |
Featured News
NEU
Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
CDX (ASX) Chart |